Cat. No.: HY-14650

DHEA

(Synonyms: Prasterone; Dehydroisoandrosterone; Dehydroepiandrosterone)

51 Cited Publications

Customer Review

Based on 51 publication(s) in Google Scholar

DHEA (Prasterone) is one of the most abundant steroid hormones. DHEA (Prasterone) mediates its action via multiple signaling pathways involving specific membrane receptors and via transformation into androgen and estrogen derivatives (e.g., androgens, estrogens, 7α and 7β DHEA, and 7α and 7β epiandrosterone derivatives) acting through their specific receptors.

For research use only. We do not sell to patients.

Purity: 99.94%
CAS No.: 53-43-0
Formula: C₁₉H₂₈O₂
Molecular Weight:288.42

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

DHEA Chemical Structure

CAS No.: 53-43-0

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (51)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

Human Endogenous Metabolite

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	>50 μM Compound: DHEA	Cytotoxic activity against human A431 cells after 24 hrs by MTT assay Cytotoxic activity against human A431 cells after 24 hrs by MTT assay	[PMID: 25456391]
A-431	IC₅₀	>50 μM Compound: DHEA	Cytotoxic activity against human A431 cells after 48 hrs by MTT assay Cytotoxic activity against human A431 cells after 48 hrs by MTT assay	[PMID: 25456391]
A549	IC₅₀	>20 μM Compound: c1	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
A549	IC₅₀	47.8 μM Compound: DHEA	Cytotoxic activity against human A549 cells after 24 hrs by MTT assay Cytotoxic activity against human A549 cells after 24 hrs by MTT assay	[PMID: 25456391]
A549	IC₅₀	47.8 μM Compound: DHEA	Cytotoxic activity against human A549 cells after 48 hrs by MTT assay Cytotoxic activity against human A549 cells after 48 hrs by MTT assay	[PMID: 25456391]
CHO	EC₅₀	3.33 μM Compound: 49	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]
DU-145	IC₅₀	>50 μM Compound: DHEA	Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay	[PMID: 26866967]
HCT-116	IC₅₀	>50 μM Compound: DHEA	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay	[PMID: 26866967]
HEK293	EC₅₀	>10 μM Compound: 19	Binding affinity to FLAG/tGFP-tagged NPC1 I1061T mutant (unknown origin) expressed in HEK293 cells assessed as localization after 24 hrs by fluorescence microscopy Binding affinity to FLAG/tGFP-tagged NPC1 I1061T mutant (unknown origin) expressed in HEK293 cells assessed as localization after 24 hrs by fluorescence microscopy	[PMID: 24928400]
HEK-293T	IC₅₀	24.9 μM Compound: 1, DHEA, dehydroepiandrosterone	Inhibition of G6PD in HEK293T cells assessed as accumulation of 6-phosphogluconate after 5 hrs by LC-MS/MS analysis using 6-aminonicotinamide Inhibition of G6PD in HEK293T cells assessed as accumulation of 6-phosphogluconate after 5 hrs by LC-MS/MS analysis using 6-aminonicotinamide	[PMID: 22506561]
HeLa	IC₅₀	>50 μM Compound: DHEA	Cytotoxic activity against human HeLa cells after 24 hrs by MTT assay Cytotoxic activity against human HeLa cells after 24 hrs by MTT assay	[PMID: 25456391]
HeLa	IC₅₀	>50 μM Compound: DHEA	Cytotoxic activity against human HeLa cells after 48 hrs by MTT assay Cytotoxic activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25456391]
HepG2	IC₅₀	>50 μM Compound: DHEA	Cytotoxic activity against human HepG2 cells after 24 hrs by MTT assay Cytotoxic activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 25456391]
HepG2	IC₅₀	>50 μM Compound: DHEA	Cytotoxic activity against human HepG2 cells after 48 hrs by MTT assay Cytotoxic activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25456391]
HL-60	IC₅₀	>20 μM Compound: c1	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
HL-60	IC₅₀	>50 μM Compound: DHEA	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 96 hrs by MTS assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 96 hrs by MTS assay	[PMID: 26866967]
HT-29	IC₅₀	>50 μM Compound: DHEA	Cytotoxic activity against human HT-29 cells after 24 hrs by MTT assay Cytotoxic activity against human HT-29 cells after 24 hrs by MTT assay	[PMID: 25456391]
HT-29	IC₅₀	>50 μM Compound: DHEA	Cytotoxic activity against human HT-29 cells after 48 hrs by MTT assay Cytotoxic activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 25456391]
HT-29	IC₅₀	>50 μM Compound: DHEA	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay	[PMID: 26866967]
J774.2	CC₅₀	198.17 μM Compound: 1a; DHEA	Cytotoxicity against mouse J774.2 cells assessed as reduction in cell viability measured after 48 hrs by resazurin dye based assay Cytotoxicity against mouse J774.2 cells assessed as reduction in cell viability measured after 48 hrs by resazurin dye based assay	[PMID: 34571489]
J774.A1	IC₅₀	141 nM Compound: 1, DHEA	Inhibition of LPS-induced TNFalpha production in mouse J774A.1 cells Inhibition of LPS-induced TNFalpha production in mouse J774A.1 cells	[PMID: 17892941]
Jurkat	IC₅₀	46.5 μM Compound: DHEA	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability after 96 hrs by MTS assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability after 96 hrs by MTS assay	[PMID: 26866967]
LNCaP	IC₅₀	>50 μM Compound: DHEA	Cytotoxic activity against human LNCAP cells after 24 hrs by MTT assay Cytotoxic activity against human LNCAP cells after 24 hrs by MTT assay	[PMID: 25456391]
LNCaP	IC₅₀	>50 μM Compound: DHEA	Cytotoxic activity against human LNCAP cells after 48 hrs by MTT assay Cytotoxic activity against human LNCAP cells after 48 hrs by MTT assay	[PMID: 25456391]
LNCaP	IC₅₀	>50 μM Compound: DHEA	Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay	[PMID: 26866967]
MCF7	IC₅₀	>20 μM Compound: c1	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
MCF7	IC₅₀	>200 μM Compound: DHEA	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23880359]
MCF7	IC₅₀	>50 μM Compound: DHEA	Cytotoxic activity against human MCF7 cells after 24 hrs by MTT assay Cytotoxic activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 25456391]
MCF7	IC₅₀	>50 μM Compound: DHEA	Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25456391]
MCF7	IC₅₀	>50 μM Compound: DHEA	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay	[PMID: 26866967]
MDA-MB-231	IC₅₀	>50 μM Compound: DHEA	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay	[PMID: 26866967]
PC-12	IC₅₀	0.29 nM Compound: DHEA	Neuroprotective activity in rat PC12 cells assessed as inhibition of serum deprivation-induced apoptosis after 24 hrs by APO Percentage apoptosis assay Neuroprotective activity in rat PC12 cells assessed as inhibition of serum deprivation-induced apoptosis after 24 hrs by APO Percentage apoptosis assay	[PMID: 19845386]
PC-12	IC₅₀	1.65 nM Compound: DHEA	Displacement of [3H]DHEA from DHEA-binding site in rat PC12 cell membranes by gamma-scintillation counting Displacement of [3H]DHEA from DHEA-binding site in rat PC12 cell membranes by gamma-scintillation counting	[PMID: 19845386]
SMMC-7721	IC₅₀	>20 μM Compound: c1	Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
SW480	IC₅₀	>20 μM Compound: c1	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
T47D	IC₅₀	2.55 μM Compound: DHEA	Antiproliferative activity against human T47D cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay Antiproliferative activity against human T47D cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay	[PMID: 26866967]

In Vitro

DHEA (Prasterone) is an effective antiapoptotic factor, reversing the serum deprivation-induced apoptosis in prostate cancer cells (DU145 and LNCaP cell lines) as well as in colon cancer cells (Caco2 cell line). DHEA (Prasterone) significantly reduces serum deprivation-induced apoptosis in all 3 cancer cell types, quantitated with the APOPercentage assay (apoptosis is reduced from 0.587±0.053 to 0.142±0.0016 or 0.059±0.002 after treatment for 12 hours with DHEA or NGF, respectively; n=3, P<0.01), and by flow cytometry analysis (FACS) for DU145 cells. The antiapoptotic effect of DHEA is dose dependent with an EC50 at nanomolar concentrations (EC₅₀: 11.2±3.6 nM and 12.4±2.2 nM in DU145 and Caco2 cells, respectively)^[1]. DHEA (Prasterone) is the principal sex steroid precursor in humans and can be converted directly to androgens. DHEA (Prasterone) (≥1 μM) causes a dose-dependent inhibition of Chub-S7 proliferation, as assessed by thymidine incorporation assays. DHEA (Prasterone) treatment inhibits expression of the key glucocorticoid-regulating genes H6PDH (≥100 nM) and HSD11B1 (≥1 μM) in differentiating preadipocytes in a dose-dependent manner. In keeping with this finding, DHEA (Prasterone) treatment (≥1 μM) results in a marked reduction in 11β-HSD1 oxoreductase activity (≥1 μM) and a concurrent increase in dehydrogenase activity at the highest DHEA dose used (25 μM DHEA) in differentiated adipocytes^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

DHEA (Prasterone) in the diet (0.45 % w/w) of male B6 mice (groups of five mice) treated for 8 weeks led to significant decreases in body temperature compared with mice fed the control AIN-76A diet. A similar comparison indicated that control and pair-fed mice are also significantly different. Animals fed DHEA (Prasterone) have significantly lower temperatures than mice fed the control diet 26/29 times tested; mice pair fed to those on the DHEA (Prasterone) diet are less affected, with 8/29 values significantly lower than in mice fed AIN-76A ad libitum. The temperatures of mice fed DHEA (Prasterone) or pair fed to DHEA (Prasterone) are significantly different 21/29 times tested. Body weights are significantly greater in mice fed the control diet than in mice fed DHEA or pair fed to DHEA (Prasterone). Food intake (grams per day) from cages are averaged for each week (n=7), except for Week 9 (n=3). The amount of food intake is significantly decreased in mice fed DHEA (Prasterone). By design, mice pair fed to DHEA (Prasterone) ate about the same amount. Thus, it appears that DHEA (Prasterone) reduces body temperature by food restriction and by a separate mechanism^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 53-43-0
Appearance Solid
Molecular Weight 288.42
Formula C₁₉H₂₈O₂
Color White to off-white
SMILES

O=C1CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@@]21C
Synonyms

Prasterone; Dehydroisoandrosterone; Dehydroepiandrosterone
Structure Classification
- Steroids
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (51)

All Histological Imaging/StainingWBIn Vivo Efficacy StudyRT-PCR

Sort by:

Journal Impact Factor

Nature

Structure and mechanism of the human bile acid transporter OSTα-OSTβ. [Abstract]

2026 Mar;651(8104):251-259. PMID: 41606314
Cell Metab

Sensing steroid hormone 17α-hydroxypregnenolone by GPR56 enables protection from ferroptosis-induced liver injury. [Abstract]

2024 Nov 5;36(11):2402-2418.e10. PMID: 39389061
Adv Funct Mater

2025 Nov 17.
Nat Commun

Androgens drive SLC1A5-dependent metabolic reprogramming in polycystic ovary syndrome. [Abstract]

2025 Aug 15;16(1):7611. PMID: 40817119

DHEA purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 15;16(1):7611. [Abstract]

Representative images of hematoxylin and eosin (HE) staining and MALDI mass spectrometry imaging of Gln on murine ovaries. Gln levels increased within granulosa cells of the DHEA (600 mg/kg; i.p.; 21 consecutive days) group.

DHEA purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 15;16(1):7611. [Abstract]

Western blots analysis of SLC1A5 and HDAC5 were significantly elevated, whereas CYP19A1 decreased. in the ovaries of Control and DHEA (600 mg/kg; i.p.; 21 consecutive days)-treated mice.

DHEA purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 15;16(1):7611. [Abstract]

mRNA expression of SLC1A5 and HDAC5 were significantly elevated, whereas CYP19A1 decreased in ovaries collected from Control and DHEA (600 mg/kg; i.p.; 21 consecutive days)-treated mice determined by qPCR.
Nat Chem Biol

Structures of the ADGRG2-Gs complex in apo and ligand-bound forms. [Abstract]

2022 Nov;18(11):1196-1203. PMID: 35982227
Proc Natl Acad Sci U S A

Progesterone activates GPR126 to promote breast cancer development via the Gi pathway. [Abstract]

2022 Apr 12;119(15):e2117004119. PMID: 35394864
Cell Commun Signal

Bisphenol a downregulates GLUT4 expression by activating aryl hydrocarbon receptor to exacerbate polycystic ovary syndrome. [Abstract]

2024 Jan 10;22(1):28. PMID: 38200540

DHEA purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2024 Jan 10;22(1):28. [Abstract]

Representative ovary sections were stained with H&E, DHEA (60 mg/kg/day; s.c.; 21 days) treatment resulted in a higher number of cystic follicles, thinner granulosa cell layers, and a lower number of corpora lutea compared to the control treatment.

DHEA purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2024 Jan 10;22(1):28. [Abstract]

DHEA (60 mg/kg/day; s.c.; 21 days)-induced PCOS mice, gained body weight.
Acta Pharmacol Sin

The classical D1 dopamine receptor antagonist SCH23390 is a functional sigma-1 receptor allosteric modulator. [Abstract]

2024 Aug;45(8):1582-1590. PMID: 38605179
Phytomedicine

Palmitic acid enhances the sensitivity of ferroptosis via endoplasmic reticulum stress mediated the ATF4/TXNIP Axis in polycystic ovary syndrome. [Abstract]

2025 Jul:142:156777. PMID: 40393214
Free Radic Biol Med

Platycodin D ameliorates polycystic ovary syndrome-induced ovarian damage by upregulating CD44 to attenuate ferroptosis. [Abstract]

2024 Sep 23:S0891-5849(24)00680-4. PMID: 39321891
J Hazard Mater Lett

2025 Nov.
Environ Pollut

Letrozole induced a polycystic ovary syndrome model in zebrafish by interfering with the hypothalamic-pituitary-gonadal axis. [Abstract]

2024 Apr 15:347:123723. PMID: 38452838
Cell Rep

Sepsis induces non-classic innate immune memory in granulocytes. [Abstract]

2023 Aug 28;42(9):113044. PMID: 37643085
Anal Chem

High-Throughput Reactive Desorption Electrospray Ionization Mass Spectrometry for Targeted Derivatization and Analysis of Poorly Ionized Small Molecules. [Abstract]

2026 Jun 16;98(23):16962-16970. PMID: 42223360
Mol Med

Androgens alleviate the depression-like phenotype in female mice by inhibiting AVPR1a in the hippocampal brain region. [Abstract]

2025 May 29;31(1):210. PMID: 40437391
Phytother Res

Hesperidin Inhibits Oxidative Stress and Apoptosis of Granulosa Cells in Polycystic Ovarian Syndrome Through the JAK2/STAT3 and PI3K/AKT Pathways. [Abstract]

2025 Sep 27. PMID: 41014201
Phytother Res

Carnosol inhibits KGN cells oxidative stress and apoptosis and attenuates polycystic ovary syndrome phenotypes in mice through Keap1-mediated Nrf2/HO-1 activation. [Abstract]

2023 Apr;37(4):1405-1421. PMID: 36786429
Cell Mol Life Sci

Melatonin refines ovarian mitochondrial dysfunction in PCOS by regulating the circadian rhythm gene Clock. [Abstract]

2025 Mar 6;82(1):104. PMID: 40047877
Cancer Cell Int

RORα inhibits gastric cancer proliferation through attenuating G6PD and PFKFB3 induced glycolytic activity. [Abstract]

2024 Jan 6;24(1):12. PMID: 38184549
Biochem Pharmacol

Unveiling ODP4: A breakthrough in PCOS treatment via BAT transplantation. [Abstract]

2025 Jun:236:116871. PMID: 40090595
J Ethnopharmacol

She ethnomedicine ameliorates ovarian dysfunction through enhanced cellular proliferation and anti-inflammation. [Abstract]

2025 Jul 14;353(Pt A):120294. PMID: 40669675
Int J Mol Sci

Analysis of GCRV Pathogenesis and Therapeutic Measures Through Proteomic and Metabolomic Investigations in GCRV-Infected Tissues of Grass Carp (Ctenopharyngodon idella). [Abstract]

2024 Nov 4;25(21):11852. PMID: 39519403
Am J Physiol Cell Physiol

Umbilical cord mesenchymal stem cells-derived extracellular vesicles improve excessive autophagy of granulosa cells through METTL3. [Abstract]

2025 May 1;328(5):C1586-C1604. PMID: 40106233
Reprod Biol Endocrinol

Liraglutide improves follicle development in polycystic ovary syndrome by inhibiting CXCL10 secretion. [Abstract]

2024 Aug 6;22(1):98. PMID: 39107809
Eur J Pharmacol

Dapagliflozin attenuates fat accumulation and insulin resistance in obese mice with polycystic ovary syndrome. [Abstract]

2024 Jun 14:176742. PMID: 38880216
Int Immunopharmacol

Dehydroepiandrosterone attenuated the immune escape of oral squamous cell carcinoma through NF-κB p65/miR-15b-5p/B7-H4 axis. [Abstract]

2024 Jun 16:137:112480. PMID: 38885603
Int Immunopharmacol

Gut microbiota dysbiosis-derived macrophage pyroptosis causes polycystic ovary syndrome via steroidogenesis disturbance and apoptosis of granulosa cells. [Abstract]

2022 Jun:107:108717. PMID: 35334358
Biol Res

Acupuncture regulates the apoptosis of ovarian granulosa cells in polycystic ovarian syndrome-related abnormal follicular development through LncMEG3-mediated inhibition of miR-21-3p. [Abstract]

2023 Jun 12;56(1):31. PMID: 37303036
Biochim Biophys Acta Mol Basis Dis

Circ_0075691 regulates lipid metabolism in granulosa cells by interacting with EIF4A3 to promote PTGS2 mRNA stability. [Abstract]

2026 Jan 26;1872(4):168173. PMID: 41605366
FASEB J

Reverse Effects of Nicotinamide Mononucleotide Supplementation on Declining Quality of Oocytes With Polycystic Ovary Syndrome. [Abstract]

2025 Jul 31;39(14):e70846. PMID: 40678956
J Ovarian Res

Nicotinamide riboside supplementation ameliorates ovarian dysfunction in a PCOS mouse model. [Abstract]

2025 Jan 20;18(1):9. PMID: 39833950
J Ovarian Res

Interlukin-22 improves ovarian function in polycystic ovary syndrome independent of metabolic regulation: a mouse-based experimental study. [Abstract]

2024 May 11;17(1):100. PMID: 38734641
Biochim Biophys Acta Mol Basis Dis

Rhythm gene PER1 mediates ferroptosis and lipid metabolism through SREBF2/ALOX15 axis in polycystic ovary syndrome. [Abstract]

2024 Jun;1870(5):167182. PMID: 38653359
J Funct Foods

2026 Mar 11.
Aging

Sigma-1 receptor is involved in diminished ovarian reserve possibly by influencing endoplasmic reticulum stress-mediated granulosa cells apoptosis. [Abstract]

2020 May 14;12(10):9041-9065. PMID: 32409627
Talanta Open

2025 Apr 25.
Biochim Biophys Acta Mol Cell Res

SFRP4 contributes to insulin resistance-induced polycystic ovary syndrome by triggering ovarian granulosa cell hyperandrogenism and apoptosis through the nuclear β-catenin/IL-6 signaling axis. [Abstract]

2024 Aug 17:119822. PMID: 39159685
Am J Pathol

Dehydroepiandrosterone Prevents Collagen Loss by Regulating HIF-1α Expression and Mitophagy in Hypoxic Human Scleral Fibroblasts. [Abstract]

2025 Sep 12:S0002-9440(25)00342-6. PMID: 40946797
Mol Cell Endocrinol

Downregulation of CASC15 attenuates the symptoms of polycystic ovary syndrome by affecting granulosa cell proliferation and regulating ovarian follicular development. [Abstract]

2024 Jun 26:112322. PMID: 38942281
Mol Cell Endocrinol

Inhibition of Nicotinamide adenine dinucleotide phosphate oxidase 4 attenuates cell apoptosis and oxidative stress in a rat model of polycystic ovary syndrome through the activation of Nrf-2/HO-1 signaling pathway. [Abstract]

2022 Jun 15;550:111645. PMID: 35413388
Mol Hum Reprod

Interleukin-22 improves ovulation in polycystic ovary syndrome via STAT3 signaling. [Abstract]

2024 Oct 12;30(10):gaae037. PMID: 39423135
Andrology

Trps1 targets Ccnd1 to regulate mouse Leydig cell proliferation. [Abstract]

2021 Nov;9(6):1923-1933. PMID: 34185441
Toxicol Appl Pharmacol

Icariin protects mouse Leydig cell testosterone synthesis from the adverse effects of di(2-ethylhexyl) phthalate. [Abstract]

2019 Sep 1:378:114612. PMID: 31175881
Mol Reprod Dev

Effect of berberine combined with metformin on autophagy in polycystic ovary syndrome by regulating AMPK/AKT/mTOR pathway. [Abstract]

2024 Aug;91(8):e23768. PMID: 39155689
J Biochem Mol Toxicol

Lycopene Ameliorates Polycystic Ovary Syndrome in Rats by Inhibiting Ovarian Ferroptosis Through Activation of the AMPK/Nrf2 Pathway. [Abstract]

2025 Feb;39(2):e70158. PMID: 39871526
Theriogenology

LH promotes testosterone synthesis in rooster leydig cells through YAP1/ACSL4/SOAT1 pathway. [Abstract]

2026 Apr 1:254:117813. PMID: 41529502
Reprod Sci

Kuntai Capsules Improve Premature Ovarian Failure by Regulating AMPK-Mediated Autophagy. [Abstract]

2025 Aug 11. PMID: 40789984
Theriogenology

Melatonin inhibits testosterone synthesis in Roosters Leydig cells by regulating lipolysis of lipid droplets. [Abstract]

2022 Sep 1:189:118-126. PMID: 35753225
Gene

Bisphenol A alters JUN promoter methylation, impairing steroid metabolism in placental cells and linking to sub-representative phenotypes. [Abstract]

2025 Jan 2:149210. PMID: 39755265
Gynecol Endocrinol

Hsa_circ_0020491 promotes polycystic ovary syndrome by interacting with IGF2BP2 through regulation of granular cell autophagy and mitochondrial dysfunction. [Abstract]

2025 Dec;41(1):2536579. PMID: 40739999
SSRN

2025 Dec 15.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (173.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 40 mg/mL (138.69 mM; ultrasonic and warming and heat to 60°C)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4672 mL

17.3358 mL

34.6717 mL

5 mM

0.6934 mL

3.4672 mL

6.9343 mL

10 mM

0.3467 mL

1.7336 mL

3.4672 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.67 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.67 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.67 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.67 mM); Clear solution

Protocol 5

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (4.33 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 6

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.25 mg/mL (4.33 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil

Solubility: 3.57 mg/mL (12.38 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[2]

Chub-S7 preadipocytes and human primary preadipocytes are seeded into a 24-well plate at densities 1×10⁵ and 2.5×10⁵ respectively. Following overnight culture, medium is supplemented with DHEA, androstenediol, or DHEA (Prasterone) (0-100 μM). Following 24-, 48-, or 72 h incubation, cell proliferation is assessed by incubation with radiolabeled thymidine (0.2 μCi/well) for the final 6 h of culture. Proteins are precipitated with TCA, and cells are scraped in NaOH. The respective content of radiolabeled nuclear material in the resulting lysates is analyzed by scintillation counting^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

Mice^[3]
Mice are fed Purina Lab Chow until the start of experiments (Day 0). Groups of five mice are then fed pelleted AIN-76A diet containing either no additive or DHEA (0.45% w/w) between 0900 and 1000 hr. Diets are stored at 4°C for no longer than six months to maintain optimal activity. Mice are given the diets ad libitum, except for mice that are pair fed to mice treated with DHEA (Prasterone). The amounts of AIN-76A diet the pair-fed mice received are determined by the weight of food consumed by the DHEA-fed mice on a daily basis. Body weights (grams) are measured at different time points starting at Day 1 and ending at Day 59. Daily food intakes (grams per day) are determined by weighing the food consumed per cage of five mice. The mean±SEM values are calculated for weeks 1 to 8 (n=7); week 9 had only 3 days.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Anagnostopoulou V, et al. Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: the role of nerve growth factor (NGF) receptors. Endocrinology. 2013 Jul;154(7):2446-56. [Content Brief]

[2]. McNelis JC, et al. Dehydroepiandrosterone exerts anti-glucocorticoid action on human preadipocyte proliferation, differentiation and glucose uptake. Am J Physiol Endocrinol Metab. 2013 Nov 1;305(9):E1134-44. [Content Brief]

[3]. Catalina F, et al. Decrease of core body temperature in mice by dehydroepiandrosterone. Exp Biol Med (Maywood). 2002 Jun;227(6):382-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	3.4672 mL	17.3358 mL	34.6717 mL	86.6791 mL
	5 mM	0.6934 mL	3.4672 mL	6.9343 mL	17.3358 mL
	10 mM	0.3467 mL	1.7336 mL	3.4672 mL	8.6679 mL
	15 mM	0.2311 mL	1.1557 mL	2.3114 mL	5.7786 mL
	20 mM	0.1734 mL	0.8668 mL	1.7336 mL	4.3340 mL
	25 mM	0.1387 mL	0.6934 mL	1.3869 mL	3.4672 mL
	30 mM	0.1156 mL	0.5779 mL	1.1557 mL	2.8893 mL
	40 mM	0.0867 mL	0.4334 mL	0.8668 mL	2.1670 mL
	50 mM	0.0693 mL	0.3467 mL	0.6934 mL	1.7336 mL
	60 mM	0.0578 mL	0.2889 mL	0.5779 mL	1.4447 mL
	80 mM	0.0433 mL	0.2167 mL	0.4334 mL	1.0835 mL
	100 mM	0.0347 mL	0.1734 mL	0.3467 mL	0.8668 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

DHEA

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Human Endogenous Metabolite Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-COVID-19 Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Tumorigenesis-Related Compound Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

Protein-protein Interaction Inhibitor Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Nuclear Receptor Compound Library

Off-patent Drug Library

Cysteine Targeted Covalent Library

Animal-Sourced Natural Product Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Dietary Supplement Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Human Hormone Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Lipid Metabolite Compound Library

Steroid Hormones Library

Natural Product Diversity Scaffold Library

Environmental Pollutant Compound Library

Mass Spectrometry Natural Product Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) DHEA

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (51)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

DHEA Related Classifications

Cat. No.: HY-14650